In this issue:
Nivolumab ± cisplatin + gemcitabine for biliary tract cancer
Real-world effectiveness of ustekinumab in CD
Vedolizumab effects on endoscopic and histologic remission in CD
Vedolizumab for primary sclerosing cholangitis in IBD
Conjunctivitis in dupilumab clinical trials
Rituximab for bullous pemphigoid
Tofacitinib after methotrexate withdrawal in RA
Low-dose interleukin-2 therapy in systemic lupus erythematosus
Tocilizumab ± methotrexate in early RA
Tocilizumab vs adalimumab + methotrexate in RA
Bimekizumab plus certolizumab pegol for RA
Denosumab plus conventional DMARDs for RA
Please login below to download this issue (PDF)